Experiences of Anticipated and Enacted Pre-exposure Prophylaxis (PrEP) Stigma Among Latino MSM in Los Angeles
- 244 Downloads
Latino men who have sex with men (MSM) are a group critically affected by HIV. Pre-exposure Prophylaxis (PrEP) is a biomedical prevention strategy that can help reduce new infections in this population. However, PrEP use may expose users to experiences of PrEP-related stigma. In-depth interviews conducted with Latino MSM PrEP users (N = 29) were analyzed using thematic analysis to explore experiences of PrEP stigma. Six themes emerged related to anticipated and enacted PrEP stigma: (1) Perception that PrEP users engage in risky sexual behaviors; (2) PrEP-induced conflict in relationships; (3) Perception that PrEP users are HIV-positive; (4) Generational differences in attitudes toward HIV prevention; (5) Experiences of discomfort, judgment, or homophobia from medical providers; and (6) Gay stigma related to PrEP disclosure to family. Manifestations of stigma included disapproving judgment, negative labeling, rejection, and devaluing individuals. The social consequences associated with using PrEP may deter uptake and persistence among Latino MSM.
KeywordsLatino Hispanic Men who have sex with men Pre-exposure prophylaxis Stigma
The content is solely the responsibility of the authors and does not necessarily reflect the official views of the National Institutes of Health. We thank the participants for graciously sharing their views and experiences for this study. This work was supported by the National Institute of Mental Health [Grant Nos: R21MH107339 and T32MH109205] and by the UCLA Center for HIV Identification, Prevention, and Treatment (CHIPTS) [Grant P30MH058107].
Compliance with Ethical Standards
Conflict of interest
All authors declare having no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 1.Centers for Disease Control and Prevention. Diagnosis of HIV Infection in the United States and Dependent Areas, 2016. 2017.Google Scholar
- 2.Center for Disease Control and Prevention. Lifetime risk of HIV Diagnosis. 2016.Google Scholar
- 3.Centers for Disease Control and Prevention. CDC Fact Sheet: HIV incidence—estimated annual infections in the U.S., 2008-2014 Overall and by Transmission. 2017.Google Scholar
- 4.Division of HIV and STD Programs, Los Angeles County Department of Public Health. 2014 Annual HIV/STD Surveillance Report. 2016.Google Scholar
- 8.Centers for Disease Control and Prevention. Preexposure prophylaxis for the prevention of HIV infection in the United States—2014 clinical practice guideline. 2014.Google Scholar
- 9.Centers for Disease Control and Prevention. HIV prevention pill not reaching most Americans who could benefit—especially people of color, presented at the 2018 Conference on Retroviruses and Opportunistic Infections, Boston, MA: National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Newsroom. 2018.Google Scholar
- 18.Haire BG. Preexposure prophylaxis-related stigma: strategies to improve uptake and adherence—a narrative review. HIV/AIDS (Auckland, NZ). 2015;7:241.Google Scholar
- 19.Schnarrs PW, Gordon D, Martin-Valenzuela R, et al. Perceived social norms about oral PrEP use: Differences Between African-American, Latino and White gay, bisexual and other men who have sex with men in Texas. AIDS Behav. 2018;30:1–5.Google Scholar
- 20.Goffman E. Stigma: notes on the management of spoiled identity. New York: Simon and Schuster; 2009.Google Scholar
- 22.Brooks RA, Nieto O, Landrian A, Donohoe TJ. Persistent stigmatizing and negative perceptions of pre-exposure prophylaxis (PrEP) users: implications for PrEP adoption among Latino men who have sex with men. AIDS Care. 2018;19:1–9.Google Scholar
- 26.Dubov A, Galbo P Jr, Altice FL, Fraenkel L. Stigma and shame experiences by MSM who take PrEP for HIV prevention: a qualitative study. Am J Men’s Health. 2015;12(6):1849–54.Google Scholar
- 35.Gilead Sciences, Inc. Press Release: U.S. Food and Drug Administration Approves Expanded Indication for Truvada® (Emtricitabine and Tenofovir Disoproxil Fumarate) for Reducing the Risk of Acquiring HIV-1 in Adolescents. 2018.Google Scholar
- 41.Golub SA. PrEP stigma: implicit and explicit drivers of disparity. Curr HIV/AIDS Rep. 2018;19:1–8.Google Scholar